Targovax Strengthens Management Team With the Appointment of Torbjørn Furuseth as CFO; Erik Digman Wiklund to become CBO
Published: Sep 13, 2018
OSLO, Norway, Sept. 13, 2018 /PRNewswire/ -- Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, announces the appointment of Dr. Torbjørn Furuseth as CFO, effective 24 September 2018. Dr. Erik Digman Wiklund, currently Targovax's CFO, will become Chief Business Officer, replacing Michael Bogenstaetter.
Torbjørn joins from the clinical stage pharmaceutical company Lytix Biopharma, where he has served as CFO since February 2017, developing an integrated financing strategy and raising NOK 150 million in private rounds. Prior to this, he was EVP Innovation at nutraceutical company, Aker BioMarine, where he established and led the innovation department. Torbjørn brings six years' experience as a management consultant at McKinsey & Co, where he served several pharma and healthcare clients, including the merger of three pharmaceutical companies with operations in 20 European countries.
Erik was appointed CFO of Targovax in April 2017, and led the NOK 200 million private placement in June 2017. He already plays an integral role in the Company's strategic operations and business development activities. By transitioning Erik into the CBO role, Targovax will be better able to leverage his strong scientific background in cancer research.
"We are delighted to announce the appointment of Torbjørn Furuseth as our new CFO. He brings a wealth of financial and industry experience, which will be instrumental in progressing Targovax's investor relations and strategy," said Øystein Soug, CEO of Targovax. "At the same time, Erik Digman Wiklund moves from being CFO to become Chief Business Officer, with responsibility for all our business development activities. Over the past 18 months, Erik has become a highly valued member of the Targovax team, and his deep insights in both the scientific and business aspects of biotech equips him to be a very effective CBO. Erik and Torbjørn have previously worked together both at McKinsey & Co and Aker Biomarine, I therefore look forward to harnessing their strong working relationship and driving Targovax forward as we continue to advance our immuno-oncology pipeline through clinical development."
For further information, please contact:
Renate Birkeli, Investor Relations
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Simon Conway/Stephanie Cuthbert - FTI Consulting (International)
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
http://news.cision.com/targovax/i/torbjorn-furuseth,c2486933 Torbjorn Furuseth
Company Codes: Bloomberg:TRVX@NO, ISIN:NO0010689326, Oslo:TRVX, RICS:TRVX.OL, Stockholm:TRVXO